Distinguishing Benign from Malignant Pancreatic and Periampullary Lesions Using Combined Use of 1H-NMR Spectroscopy and Gas Chromatography–Mass Spectrometry
| Autor: | Karen A. Kopciuk, Elijah Dixon, Francis R. Sutherland, Oliver F. Bathe, Yarrow J. McConnell, Aalim M. Weljie, Farshad Farshidfar, Chad G. Ball, Hans J. Vogel |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
periampullary adenocarcinoma Pathology medicine.medical_specialty Alanine levels Endocrinology Diabetes and Metabolism pancreatic cancer Combined use lcsh:QR1-502 Biochemistry Article lcsh:Microbiology 03 medical and health sciences Metabolomics Pancreatic cancer medicine Molecular Biology business.industry biomarkers medicine.disease metabolomics 030104 developmental biology Periampullary Adenocarcinoma Proton NMR Adenocarcinoma Gas chromatography–mass spectrometry business |
| Zdroj: | Metabolites, Vol 7, Iss 1, p 3 (2017) Metabolites; Volume 7; Issue 1; Pages: 3 Metabolites |
| ISSN: | 2218-1989 |
| DOI: | 10.3390/metabo7010003 |
| Popis: | Previous work demonstrated that serum metabolomics can distinguish pancreatic cancer from benign disease. However, in the clinic, non-pancreatic periampullary cancers are difficult to distinguish from pancreatic cancer. Therefore, to test the clinical utility of this technology, we determined whether any pancreatic and periampullary adenocarcinoma could be distinguished from benign masses and biliary strictures. Sera from 157 patients with malignant and benign pancreatic and periampullary lesions were analyzed using proton nuclear magnetic resonance (1H-NMR) spectroscopy and gas chromatography–mass spectrometry (GC-MS). Multivariate projection modeling using SIMCA-P+ software in training datasets (n = 80) was used to generate the best models to differentiate disease states. Models were validated in test datasets (n = 77). The final 1H-NMR spectroscopy and GC-MS metabolomic profiles consisted of 14 and 18 compounds, with AUROC values of 0.74 (SE 0.06) and 0.62 (SE 0.08), respectively. The combination of 1H-NMR spectroscopy and GC-MS metabolites did not substantially improve this performance (AUROC 0.66, SE 0.08). In patients with adenocarcinoma, glutamate levels were consistently higher, while glutamine and alanine levels were consistently lower. Pancreatic and periampullary adenocarcinomas can be distinguished from benign lesions. To further enhance the discriminatory power of metabolomics in this setting, it will be important to identify the metabolomic changes that characterize each of the subclasses of this heterogeneous group of cancers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|